Yazar "Ölmez, Ömer Fatih" için listeleme
-
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
Bilici, Ahmet; Ölmez, Ömer Fatih; Kaplan, Muhammed Ali; Öksüzoğlu, Berna; Sezer, Ahmet; Karadurmuş, Nuri; Çubukçu, Erdem; Şendur, Mehmet Ali Nahit; Aksoy, Sercan; Demirci, Umut (Taylor & Francis Ltd, 2023)AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ... -
Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Çalış, Elif; Ölmez, Ömer Fatih; Karcı, Ebru (Lippincott Williams & Wilkins, 2023)... -
Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Çalış, Elif; Kutlu, Yasin; Hamdard, Jamshid; Muğlu, Harun; Ölmez, Ömer Fatih; Karcı, Ebru; Açıkgöz, Özgür (Elsevier B.V., 2023)Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, ... -
Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Kılıçkap, Saadettin; Buğdaycı Basal, Fatma; Demirkazık, Ahmet; Gürsoy, Pınar; Demirci, Ufuk; Erman, Mustafa; Yumuk, Fulden; Çay Şenler, Filiz; Çakar, Burcu; Çiçin, İrfan; Öztürk, Akın; Coşkun, Hasan Şenol; Çubukçu, Erdem; Işıkdoğan, Abdurrahman; Ölmez, Ömer Fatih; Tatlı, Ali Murat; Karaağaç, Mehmet Onur; Sakalar, Teoman; Eralp, Yeşim; Korkmaz, Taner (Oxford University Press, 2019)Background: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþpatients who ... -
Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice
Tural, Deniz; Arslan, Çağatay; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Erman, Mustafa; Ürün, Yüksel; Karadurmuş, Nuri; Akar, Emre; Kılıçkap, Saadettin (Lippincott Williams & Wilkins, 2022)Background: Anti-tumor activity and manageable safety profile of immune checkpoint blockade therapies (ICT) have been demonstrated in previous clinical trials in patients with metastatic urothelial carcinoma. To the best ... -
Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
Kılıçkap, Saadettin; Demirci, Umut; Buğdaycı, Fatma; Tural, Deniz; Korkmaz, Taner; Paydaş, Semra; Yılmaz, Coşkun; Tuna, Hande; Sezer, Ahmet; Yeşil Çinkir, Havva; Erman, Münire; Eralp, Yeşim; Çabuk, Devrim; Işıkdoğan, Abdurrahman; Demirkazık, Ahmet; Karaoğlu, Aziz; Yazılıtaş, Doğan; Çay Şenler, Filiz; Yumuk, Perran Fulden; Coşkun, Hatice; Yıldız, İbrahim; Öztop, İlhan; Beypınar, İsmail; Aydın, Kübra; Kaplan, M.; Meydan, Nezih; Ölmez, Ömer Fatih; Seber, Samile; Arslan, Çağatay; Şendur, Mehmet Ali Nahit; Çiçin, İrfan (Elsevier Science, 2019)Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK ... -
Major and minor salivary gland cancers: A multicenter retrospective study
Hacıoğlu, Muhammet Bekir; Erdoğan, Bülent; Bardakçı, Murat; Algın, Efnan; Gülbağcı, Burcu; Hacıbekiroğlu, İlhan; Hamdard, Jamshid; Ölmez, Ömer Fatih; Akkuş, Hadi; Çiçin, İrfan (John Wiley and Sons Inc, 2023)BackgroundMost of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. ... -
Metastatik meme kanseri tedavisinde lapatinib kapesitabin kombinasyonun etkinliğinin retrospektif değerlendirilmesi
Tüm dünyada meme kanseri kadınlarda kanserin ve kanser ilişkili ölümlerin en sık nedenidir. Meme kanserli hastaların %17-30 HER2overekspresyonu olup hastalık, kötü prognoz, hastalık progresyon riskinde artış, genel sağkalım ... -
The modified glasgow prognostic score (MGPS) and the mortality prediction MODEL II (MPM II) CAN predict mortality in patients with breast cancer admitted to intensive care: A retrospective cohort study
Ölmez, Ömer Fatih; Tunay, Burcu; Bilici, Ahmet; Bayramgil, Ayberk; Çavuşoğlu, Güneş Dorukhan; Öz, Hüseyin (Lippincott Williams and Wilkins, 2022)... -
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
Kutlu, Yasin; Göktaş Aydın, Sabin; Bilici, Ahmet; Öven, Bala Başak; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Hamdard, Jamshid (NLM (Medline), 2023)Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy ... -
The optimal treatment approaches and prognostic factors in elderly patients with advanced stage biliary tract tumors
Göktaş Aydın, Sabin; Çakan Demirel, Burçin; Bilici, Ahmet; Yılmaz, Cansu; Topçu, Atakan; Aykan, Musa Barış; Kahraman, Seda; Atcı, Muhammed Mustafa; Akbıyık, Ilgın; Akgül, Fahri; Ölmez, Ömer Fatih; Aydın, Ahmet (Ankara Hematology Oncology Association, 2023)Introduction: There is a lack of evidence of the outcomes in elderly patients advanced stage biliary tract cancer due to the patients aged over 65 years are less than 25% in many prospective trials. We designed a retrospective ... -
Papilödem: Leptomeninjiyal metastazın önemli klinik işareti olabilir mi?
Arıcı Düz, Özge; Olmuşçelik, Oktay; Çadırcı, Fadime; Ölmez, Ömer Fatih (Galenos Yayıncılık, 2020)Amaç: Leptomeninjiyal metastaz (LM) tüm kanser tiplerinde izlenebilen nadir ancak kötü prognozlu bir klinik tablodur. Tanı, tedavi ve prognoz hastalığı yönetmekte önemli süreçlerdendir. Bu amaçla LM klinik ve laboratuvar ... -
Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
Açıkgöz, Özgür; Çakan, Burçin; Demir, Tarık; Bilici, Ahmet; Öven, Bala Başak; Hamdard, Jamshid; Olmuşçelik, Oktay; Ölmez, Ömer Fatih; Şeker, Mesut; Yıldız, Özcan (Lippincott Williams & Wilkins, 2021)The aim of this study was to investigate the predictive and prognostic value of PLR, and the relationship between PLR and tumor localization. A total of 229 patients with de-novo metastatic CRC were retrospectively analyzed. ... -
Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Bilici, Ahmet; Çakan, Banu; Demir, Tarık; Öven, Bala Başak; Açıkgöz, Özgür; Hamdard, Jamshid; Ölmez, Ömer Fatih; Ölmüşçelik, Olcay; Şeker, Mesut; Yıldız, Özcan (Oxford University Press, 2019)Background The prognostic importance of platelet-to-lymphocyte ratio(PLR)has been also investigated in some cancer types including colorectal cancer (CRC).Several studies have found that PLR is associated with poor prognosis ... -
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Göktaş Aydın, Sabin; Kutlu, Yasin; Muğlu, Harun; Aydın, Ahmet; Açıkgöz, Özgür; Hamdard, Jamshid; Karcı, Ebru; Bilici, Ahmet; Ölmez, Ömer Fatih; Yıldız, Özcan (Springer, 2024)Background: Prostate cancer is a prevalent cancer in men worldwide, and castration-resistant prostate cancer (CRPC) is characterized by disease progression despite androgen deprivation therapy. While clinical and prognostic ... -
Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: Single center experience from Turkey
Açıkgöz, Özgür; Yıldız, Anıl; Bilici, Ahmet; Ölmez, Ömer Fatih; Basım, Pelin; Çakır, Aslı (Lippincott Williams and Wilkins, 2022)The aim of this study was to investigate the predictive value of PLR and NLR as an indicator of pathological complete response (pCR) in patients with breast cancer after NACT. One hundred thirty-nine patients with early ... -
The prevalence of drug-drug interactions and reported therapy related side-effects in oncology out-patients
Umar, Rashida Muhammad; Can, Zeynep Yeşim; Güven Eke, Ece; Karataş Koçberber, Emine; Ölmez, Ömer Fatih (Marmara University, 2023)Objective: The use of multiple medications in cancer patients is unavoidable; thus, adverse drug-drug interactions are frequent. This study aims to assess the prevalence of potential drug interactions in oncology patients ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Akar, Ebru; Çakar, Bilge; Köstek, Osman; Ekenel, Mahmut; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy, Fatma; Oruç, Korkmaz; Bayram, Süleyman Nuri; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Artaç, Macide (Elsevier, 2020)Background: In the current study, we evaluated pretreatment prognostic factors foroverall survival (OS) in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin; Artaç, Mehmet (Springer Japan KK, 2021)Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab ...